Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Wits Ezintsha
HIV, obesity, and stigma: lessons for programmes, policy, and practice
FREE with registration! Log in or register to access the full article. References 1. Earnshaw, VA ∙ Chaudoir, SR From conceptualizing to measuring HIV stigma: a review of HIV stigma mechanism measures AIDS Behav. 2009; 13:1160-1177 2. Global Network of People Living with HIV The People Living with HIV Stigma Index 2.0: Implementation Guidelines 3. Parker, R ∙ Aggleton, P HIV and AIDS-related stigma and discrimination: a conceptual framework and implications for action Soc Sci Med. 2003; 57:13-24 4.
Antiretroviral therapy, adiposity, and cardiometabolic risk in people with HIV
FREE with registration! Log in or register to access the full article. References 1. Pryke, L ∙ Koethe, JR ∙ Bailin, S Obesity and weight management in HIV: epidemiology, complications, and emerging treatments Curr HIV/AIDS Rep. 2026; 23:1 2. Capeau, J ∙ Lagathu, C ∙ Béréziat, V Recent data on the role of antiretroviral therapy in weight gain and obesity in persons living with HIV Curr Opin HIV AIDS. 2024; 19:14-20 3. Sax, PE ∙ Erlandson, KM ∙ Lake, JE ∙ et al.
The Need for Lenacapavir Compulsory Licences in Ending the HIV Epidemic
PDF Split View Andrew Hill, Mark J Siedner, Cassandra Fairhead, Francois Venter, The Need for Lenacapavir Compulsory Licences in Ending the HIV Epidemic, Clinical Infectious Diseases, 2025;, ciaf115, https://doi.org/10.1093/cid/ciaf115 Close HIV, pre-exposure prophylaxis, licence, transmission Despite numerous effective strategies to prevent human immunodeficiency virus (HIV) transmission, there were 1.3 million new HIV infections globally in 2023 [1].
GLP-1 Receptor Agonists and the Path to Sustainable Obesity Care
GLP-1 Receptor Agonists and the Path to Sustainable Obesity Care As of 2024, more than 1 billion people are estimated to be living with obesity worldwide.1 The glucagon-like peptide-1 receptor agonist (GLP-1RA) and closely related glucose-dependent insulinotropic polypeptide (GIP/GLP-1) dual agonist medication classes offer a promising strategy to treat obesity and prevent its downstream health complications.
The cost of adding rapid screening for diabetes, hypertension, and COVID-19 to COVID-19 vaccination queues in Johannesburg, South Africa - BMC Public Health
We conducted a prospective cost analysis at three public sector PHCs in Johannesburg, Gauteng Province, South Africa, Yeoville Recreational Centre, Hillbrow Community Health Centre, and Clermont Clinic, as well as one academic hospital (Charlotte Maxeke Johannesburg Academic Hospital, CMJAH). The first two facilities serve participants residing in inner-city residential neighbourhoods, while CMJAH provides services to the entire province.
Integration of point-of-care screening for type 2 diabetes mellitus and hypertension into the COVID-19 vaccine programme in Johannesburg, South Africa | BMC Public Health | Full Text
Table 1 provides data on the demographic and health-related characteristics of the study population, which consisted of 1,376 individuals. Among the participants, 638 (46.4%) were male and 738 (53.6%) were female. Most participants were in the 30–39 age group (32.5%), followed by the 18–29 age group (23.0%). The median age for both males and females was 38 years (interquartile range (IQR): 30.0, 47.0). A total of 742 participants (53.9%) were classified as pre-obese, obese, or severely obese.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Wits
Contact Wits, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack